SAN DIEGO, Sept. 8 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced that it is offering to sell 8.3 million shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. Barclays Capital Inc. is the sole book-running manager of the offering and Halozyme has granted the underwriter a thirty (30) day option to purchase up to 1,245,000 additional shares. Halozyme intends to use the net proceeds from the offering for general corporate purposes and to support further research and development of its product candidates.
